Agenus Inc. (AGEN)
AGEN Stock Price Chart
Explore Agenus Inc. interactive price chart. Choose custom timeframes to analyze AGEN price movements and trends.
AGEN Company Profile
Discover essential business fundamentals and corporate details for Agenus Inc. (AGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Feb 2000
Employees
316.00
Website
https://www.agenusbio.comCEO
Garo H. Armen
Description
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Financial Timeline
Browse a chronological timeline of Agenus Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is $0.05, while revenue estimate is $34.00m.
Earnings released on 11 May 2026
EPS came in at $1.02 falling short of the estimated $2.10 by -51.43%, while revenue for the quarter reached $33.70m , missing expectations by -73.98%.
Earnings released on 16 Mar 2026
EPS came in at $0.56 surpassing the estimated -$1.27 by +144.09%, while revenue for the quarter reached $34.20m , beating expectations by +21.73%.
Earnings released on 10 Nov 2025
EPS came in at $1.94 falling short of the estimated $2.63 by -26.24%, while revenue for the quarter reached $30.24m , beating expectations by +7.61%.
Earnings released on 11 Aug 2025
EPS came in at -$1.00 falling short of the estimated -$0.78 by -28.21%, while revenue for the quarter reached $25.69m , beating expectations by +2.85%.
Earnings released on 12 May 2025
EPS came in at -$1.03 surpassing the estimated -$1.61 by +36.02%, while revenue for the quarter reached $24.07m , beating expectations by +8.94%.
Earnings released on 11 Mar 2025
EPS came in at -$2.04 surpassing the estimated -$2.36 by +13.56%, while revenue for the quarter reached $26.84m , missing expectations by -10.82%.
Earnings released on 12 Nov 2024
EPS came in at -$3.08 falling short of the estimated -$2.33 by -32.19%, while revenue for the quarter reached $25.11m , missing expectations by -21.06%.
Earnings released on 8 Aug 2024
EPS came in at -$2.52 falling short of the estimated -$1.44 by -75.00%, while revenue for the quarter reached $23.51m , missing expectations by -61.76%.
Earnings released on 7 May 2024
EPS came in at -$3.04 surpassing the estimated -$3.22 by +5.59%, while revenue for the quarter reached $28.01m , missing expectations by -28.69%.
Stock split effective on 12 Apr 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Mar 2024
EPS came in at -$2.60 falling short of the estimated -$0.40 by -550.00%, while revenue for the quarter reached $83.80m , beating expectations by +78.11%.
Earnings released on 7 Nov 2023
EPS came in at -$3.20 surpassing the estimated -$3.80 by +15.79%, while revenue for the quarter reached $24.31m , missing expectations by -48.32%.
Earnings released on 8 Aug 2023
EPS came in at -$4.00 matching the estimated -$4.00, while revenue for the quarter reached $25.30m , beating expectations by +4.88%.
Earnings released on 9 May 2023
EPS came in at -$4.40 falling short of the estimated -$4.20 by -4.76%, while revenue for the quarter reached $22.90m , missing expectations by -0.34%.
Stock split effective on 26 Apr 2023
Shares were split 1019 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Mar 2023
EPS came in at -$4.80 falling short of the estimated -$4.40 by -9.09%, while revenue for the quarter reached $28.39m , beating expectations by +59.20%.
Earnings released on 8 Nov 2022
EPS came in at -$3.80 falling short of the estimated -$3.60 by -5.56%, while revenue for the quarter reached $22.77m , beating expectations by +10.05%.
Earnings released on 9 Aug 2022
EPS came in at -$3.40 surpassing the estimated -$4.60 by +26.09%, while revenue for the quarter reached $20.93m , beating expectations by +11.93%.
Earnings released on 10 May 2022
EPS came in at -$3.80 surpassing the estimated -$5.80 by +34.48%, while revenue for the quarter reached $25.94m , beating expectations by +119.82%.
Earnings released on 1 Mar 2022
EPS came in at -$5.20 falling short of the estimated -$3.20 by -62.50%, while revenue for the quarter reached $20.26m , missing expectations by -46.31%.
Earnings released on 9 Nov 2021
EPS came in at $13.80 surpassing the estimated $9.20 by +50.00%, while revenue for the quarter reached $252.95m , beating expectations by +38.14%.
Earnings released on 9 Aug 2021
EPS came in at -$7.40 falling short of the estimated -$4.80 by -54.17%, while revenue for the quarter reached $10.73m , meeting expectations.
AGEN Stock Performance
Access detailed AGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
